Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Moffitt Cancer Center

Sites in Tampa, FL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
711
Shown on this page
12
Current sort
Recently updated
Campus scope
Moffitt Cancer Center, Tampa, FL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Moffitt Cancer Center, Tampa, FL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 253–264 of 711 matching trials with a site at Moffitt Cancer Center, Tampa, FL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Not applicable Interventional

Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

NCT06423963
Status at this site: Recruiting
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Physical Activity, Nutrition Counseling, Resistance Training
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Active, not recruiting Phase 1 Interventional

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

NCT05809752
Site status not listed — check the official record
View directory record Official record
Conditions
Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer
Interventions
Dendritic Cell Vaccine
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Active, not recruiting Not applicable Interventional

DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

NCT03115333
Site status not listed — check the official record
View directory record Official record
Conditions
Gliosarcoma, Recurrent Glioblastoma
Interventions
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
58
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Castro Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Recruiting Phase 2 Interventional

Evaluation and Outcomes of SAVI Scout MD for Localized Breast Surgery

NCT07686250
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer
Interventions
SAVI Scout MD system
Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Not yet recruiting Not applicable Interventional

PRehabilitation Intervention to Modify Eating for Breast Cancer Patients (PRIME)

NCT07638150
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Mediterranean Diet
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Active, not recruiting Phase 3 Interventional

Intravesical BCG vs GEMDOCE in NMIBC

NCT05538663
Site status not listed — check the official record
View directory record Official record
Conditions
Non-muscle-invasive Bladder Cancer
Interventions
Gemcitabine, Docetaxel, Bacillus Calmette Guerin
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
229
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 163 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Active, not recruiting Phase 2 Interventional

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

NCT05012371
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Cabozantinib, Everolimus, Lenvatinib, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Houston, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Active, not recruiting Phase 3 Interventional

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05721755
Site status not listed — check the official record
View directory record Official record
Conditions
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Carboplatin, Cisplatin, Computed Tomography, Fluorouracil, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography, Quality-of-Life Assessment, Radiation Therapy
Drug · Procedure · Biological + 2 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
51
States / cities
Tampa, Florida • Atlanta, Georgia • Boise, Idaho + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Active, not recruiting Phase 3 Interventional

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

NCT06500455
Site status not listed — check the official record
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Stereotactic Radiosurgery
Procedure · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
262
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 189 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Recruiting Phase 2 Interventional

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

NCT02734537
Status at this site: Recruiting
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Lip and Oral Cavity Squamous Cell Carcinoma, p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
Drug · Radiation · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
679
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 450 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Active, not recruiting Phase 3 Interventional

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

NCT03267433
Site status not listed — check the official record
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human
Procedure · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years to 70 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
374
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 236 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Recruiting Phase 3 Interventional

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

NCT06724237
Status at this site: Recruiting
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy
Procedure · Other · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 75 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2075
U.S. locations
164
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 123 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 10:50 AM EDT

About this Moffitt Cancer Center institution page

What this page lists
ClinicalTrials.gov records that list Moffitt Cancer Center in Tampa, FL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.